Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul A Marks

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Expert Opinion on Investigational Drugs|November 26, 2005
Histone deacetylase inhibitors: discovery and development as anticancer agentsPaul A Marks, Milos Dokmanovic
The Journal of Clinical Investigation|November 3, 2006
A man who has made his Marks on scienceKaren Honey, Paul A Marks
Nature Clinical Practice. Oncology|November 3, 2005
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acidWilliam Kevin Kelly, Paul A Marks
Epigenomics|November 30, 2011
Histone deacetylase inhibitors in the therapy of cancer: much to learnJu-Hee Lee, Paul A Marks
Autophagy|August 17, 2012
Curbing autophagy and histone deacetylases to kill cancer cellsNoor Gammoh, Paul A Marks, Xuejun Jiang
Molecular Cancer Research : MCR|October 24, 2007
Histone deacetylase inhibitors: overview and perspectivesMilos Dokmanovic, Cathy Clarke, Paul A Marks
Current Opinion in Pharmacology|August 7, 2003
Histone deacetylasesPaul A Marks, Thomas Miller, Victoria M Richon
Expert Opinion on Investigational Drugs|November 30, 2002
Histone deacetylase inhibitors: from target to clinical trialsWilliam K Kelly, Owen A O'Connor, Paul A Marks
Proceedings of the National Academy of Sciences of the United States of America|December 15, 2004
Apoptotic and autophagic cell death induced by histone deacetylase inhibitorsYufang Shao, Zhonghua Gao, Paul A Marks, et al.
Advances in Cancer Research|October 24, 2012
Mechanisms of resistance to histone deacetylase inhibitorsJu-Hee Lee, Megan L Choy, Paul A Marks
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Expert Opinion on Investigational Drugs|November 26, 2005
Histone deacetylase inhibitors: discovery and development as anticancer agentsPaul A Marks, Milos Dokmanovic
The Journal of Clinical Investigation|November 3, 2006
A man who has made his Marks on scienceKaren Honey, Paul A Marks
Nature Clinical Practice. Oncology|November 3, 2005
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acidWilliam Kevin Kelly, Paul A Marks
Epigenomics|November 30, 2011
Histone deacetylase inhibitors in the therapy of cancer: much to learnJu-Hee Lee, Paul A Marks
Autophagy|August 17, 2012
Curbing autophagy and histone deacetylases to kill cancer cellsNoor Gammoh, Paul A Marks, Xuejun Jiang
Molecular Cancer Research : MCR|October 24, 2007
Histone deacetylase inhibitors: overview and perspectivesMilos Dokmanovic, Cathy Clarke, Paul A Marks
Current Opinion in Pharmacology|August 7, 2003
Histone deacetylasesPaul A Marks, Thomas Miller, Victoria M Richon
Expert Opinion on Investigational Drugs|November 30, 2002
Histone deacetylase inhibitors: from target to clinical trialsWilliam K Kelly, Owen A O'Connor, Paul A Marks
Proceedings of the National Academy of Sciences of the United States of America|December 15, 2004
Apoptotic and autophagic cell death induced by histone deacetylase inhibitorsYufang Shao, Zhonghua Gao, Paul A Marks, et al.
Advances in Cancer Research|October 24, 2012
Mechanisms of resistance to histone deacetylase inhibitorsJu-Hee Lee, Megan L Choy, Paul A Marks
Pageof 5